| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7653286 | Revue Francophone des Laboratoires | 2012 | 4 Pages |
Abstract
The fracture risk assessment is fundamental in the treatment of postmenopausal women in daily practice. The use of FRAX® is now given in this assessment and is included in the new recommendations of the French guidelines for the pharmacological treatment of postmenopausal osteoporosis. The bone turnover markers were not included in the FRAX®. Published studies did not find any reproducible marker that is associated with an increased risk of fracture. Recent recommendations of experts from the International osteoporosis foundation (IOF) and the International federation of clinical chemistry and laboratory medicine (IFCC) found insufficient evidence of the value of markers for the prediction of fracture risk in daily practice.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Julien Paccou,